New asthma drug AK139 enters phase 2 trial – hope for better lung function?

NCT ID NCT07436221

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests a new drug called AK139 in 160 people with moderate to severe asthma. Participants receive either AK139 or a placebo by injection under the skin. The trial measures changes in lung function and asthma control over time, while also checking for side effects. It aims to see if AK139 can help manage asthma better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK139 (a drug given by injection under the skin)
What this could lead to: If successful, this could lead to a new treatment option for people with moderate to severe asthma, helping to improve lung function and control symptoms.
What could go wrong: This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Shanghai General Hospital

Shanghai, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.